Viracta Therapeutics (VIRX) Stock Forecast, Price Target & Predictions
VIRX Stock Forecast
Viracta Therapeutics stock forecast is as follows: an average price target of $8.00 (represents a 5166.62% upside from VIRX’s last price of $0.15) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VIRX Price Target
The average price target for Viracta Therapeutics (VIRX) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 5166.62% upside from VIRX's last price of $0.15.
VIRX Analyst Ratings
According to 2 Wall Street analysts, Viracta Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VIRX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Viracta Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2022 | RBC Capital | - | - | 140.24% | 5166.62% |
The latest Viracta Therapeutics stock forecast, released on Nov 11, 2022 by RBC Capital company, set a price target of $8.00, which represents a 140.24% increase from the stock price at the time of the forecast ($3.33), and a 5166.62% increase from VIRX last price ($0.15).
Viracta Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.15 | $0.15 | $0.15 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Viracta Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Viracta Therapeutics's last price of $0.15. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 23, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Nov 11, 2022 | RBC Capital | Outperform | Outperform | Hold |
Viracta Therapeutics's last stock rating was published by Oppenheimer on May 23, 2024. The company gave VIRX a "Outperform" rating, the same as its previous rate.
Viracta Therapeutics Financial Forecast
Viracta Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $120.00K | $2.07M | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
| High Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
| Low Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.32% | 3.32% | - | - | - |
Viracta Therapeutics's average Quarter revenue forecast for Jun 20 based on 1 analysts is $375.00K, with a low forecast of $375.00K, and a high forecast of $375.00K. VIRX's average Quarter revenue forecast represents a 212.50% increase compared to the company's last Quarter revenue of $120.00K (Mar 20).
Viracta Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-79.11M | $-6.33M | $-5.81M | $-5.29M | $-5.87M | $-6.13M | $-5.60M |
| Avg Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
| High Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
| Low Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
| Surprise % | - | - | - | - | - | - | - | -87.90% | -84.33% | -77.49% | -42.34% | -146.73% | -153.20% | -93.28% |
undefined analysts predict VIRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Viracta Therapeutics's previous annual EBITDA (undefined) of $NaN.
Viracta Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-79.62M | $-6.39M | $-7.09M | $-5.36M | $-6.01M | $-6.35M | $-6.12M |
| Avg Forecast | $-6.73M | $-6.73M | $-8.71M | $-8.31M | $-7.65M | $-10.55M | $-14.45M | $-1.63B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
| High Forecast | $-6.73M | $-6.73M | $-8.71M | $-8.31M | $-7.65M | $-10.55M | $-14.45M | $-1.30B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
| Low Forecast | $-6.73M | $-6.73M | $-8.71M | $-8.31M | $-7.65M | $-10.55M | $-14.45M | $-1.96B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
| Surprise % | - | - | - | - | - | - | - | 0.05% | 0.08% | 0.07% | 0.05% | 0.05% | 0.05% | 0.03% |
Viracta Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VIRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Viracta Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $3.84M | $2.06M | $2.23M | $2.48M | $2.51M | $2.52M | $2.44M |
| Avg Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
| High Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
| Low Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
| Surprise % | - | - | - | - | - | - | - | 0.08% | 0.53% | 0.57% | 0.38% | 1.20% | 1.20% | 0.78% |
Viracta Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to VIRX last annual SG&A of $3.84M (Mar 21).
Viracta Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-5.25 | $-0.17 | $-0.19 | $-0.48 | $-0.57 | $-0.88 | $-1.03 |
| Avg Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
| High Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
| Low Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
| Surprise % | - | - | - | - | - | - | - | -225.00% | 0.09% | 0.08% | 0.19% | 0.19% | 0.25% | 0.17% |
According to undefined Wall Street analysts, Viracta Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VIRX previous annual EPS of $NaN (undefined).
Viracta Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SQZ | SQZ Bio | - | - | 90809.09% | Buy |
| VIRX | Viracta Therapeutics | - | - | 5233.33% | Buy |
| ALXO | ALX Oncology | - | - | 1799.22% | Buy |
| VINC | Vincerx Pharma | - | - | 1053.85% | Buy |
| XFOR | X4 Pharmaceuticals | - | - | 891.89% | Buy |
| CABA | Cabaletta Bio | - | - | 773.26% | Buy |
| INZY | Inozyme Pharma | - | - | 445.35% | Buy |
| BMEA | Biomea Fusion | - | - | 256.58% | Buy |
| EYPT | EyePoint Pharmaceuticals | - | - | 211.38% | Buy |
| TRVI | Trevi Therapeutics | - | - | 193.04% | Buy |
| LYRA | Lyra Therapeutics | - | - | 177.78% | Hold |
| STOK | Stoke Therapeutics | - | - | 171.52% | Buy |
| BCYC | Bicycle Therapeutics | - | - | 168.51% | Buy |
| TERN | Terns Pharmaceuticals | - | - | 149.56% | Buy |
| IGMS | IGM Biosciences | - | - | 128.68% | Buy |
| LPTX | Leap Therapeutics | - | - | 113.18% | Buy |
| MREO | Mereo BioPharma Group | - | - | 83.42% | Buy |